Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31265625 | 1.00 | LRRK2 (0.43) | LRRK2ALDH1A1DYRK1ACSNK1A1CLK4 | |
| SCHEMBL287569 | 0.84 | ALDH1A1 (0.39) | LRRK2ALDH1A1DYRK1ACSNK1A1CLK4 | |
| SCHEMBL890661 | 0.84 | LRRK2 (0.50) | LRRK2ALDH1A1DYRK1ARXFP1HTT | |
| SCHEMBL17262977 | 0.78 | HTT (0.34) | LRRK2DYRK1ACSNK1A1CLK4HTT | |
| SCHEMBL17262975 | 0.75 | PDE5A (0.35) | LRRK2HTT | |
| SCHEMBL18074893 | 0.74 | LRRK2 (0.43) | LRRK2DYRK1AEGFRERBB2RXFP1 | |
| SCHEMBL12186825 | 0.74 | LRRK2 (0.47) | LRRK2ALDH1A1DYRK1ARXFP1HTT | |
| SCHEMBL16783455 | 0.74 | DYRK1A (0.49) | LRRK2DYRK1AEGFRERBB2RXFP1 | |
| SCHEMBL12957026 | 0.74 | LRRK2 (0.43) | LRRK2DYRK1AEGFRERBB2RXFP1 | |
| SCHEMBL1109104 | 0.74 | KDM4E (0.39) | LRRK2ALDH1A1DYRK1ARXFP1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | claimed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| CN-119504755-A | Pyrazolopyrimidine compound and application thereof | 上海壹迪生物技术有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| CN-119060018-A | N, N-diaryl urea derivative and application thereof | 杭州百新生物医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452977-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-118373824-A | Substituted quinazoline-4-ketone compound and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-113512042-B | Substituted quinazoline-4-ketone compound and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151735-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151740-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | LRRK2 588/4885ALDH1A1 4783/4885DYRK1A 237/4885 |
| US-20100331306-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | LRRK2 435/4885ALDH1A1 3890/4885DYRK1A 2161/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | LRRK2 21/4885ALDH1A1 4449/4885DYRK1A 154/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | LRRK2 592/4885ALDH1A1 3879/4885DYRK1A 1807/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | LRRK2 31/4885ALDH1A1 4076/4885DYRK1A 1060/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | LRRK2 451/4885ALDH1A1 4025/4885DYRK1A 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.